Immunization Newsbriefs (c) Copyright Information Inc., Bethesda, MD. Brought to you by the National Network for Immunization Information (NNii). Visit NNii's new website at http://www.immunizationinfo.org.
------------------------------------------------------------
October 14, 2002
U.S. IMMUNIZATION NEWS
"Cancer Vaccine Test Has Promising Result"
New York Times (www.nytimes.com) (10/14/02) P. C7
Results of a clinical trial involving New York-based biotechnology company Antigenics' experimental cancer vaccine, which were published in the Journal of Clinical Oncology, determined that the vaccine was able to virtually eliminate tumors in two of 28 patients with advanced melanoma. Antigenics' vaccine, known as HSPPC-96, has a similar success rate as Interleukin-2, which is approved to treat advanced melanoma; however, HSPPC-96 shows little toxicity, unlike Interleukin-2. The Antigenics vaccine, which is in the final phase of clinical testing, is custom-made for each patient, using cells from their tumors and works by encouraging the patient's immune system to fight the cancerous cells.
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.